Enhanced antitumor efficacy of telomerase-selective oncolytic adenobiral agent OBP-301 with chemotherapy in osteosarcoma.
Project/Area Number |
24890132
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
Orthopaedic surgery
|
Research Institution | Okayama University |
Principal Investigator |
|
Project Period (FY) |
2012-08-31 – 2014-03-31
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | テロメラーゼ / ウイルス療法 / 骨肉腫 |
Research Abstract |
We investigated the chemosensitizing effect of a telomerase-specific replication-competent oncolytic adenovirus, OBP-301, in human osteosarcoma cells. OBP-301 infection enhanced the cytotoxic effect of chemotherapy and increased chemotherapy-mediated apoptosis through downregulation of Mcl-1 expression. Combination therapy significantly suppressed tumor growth in a subcutaneous xenograft model. These results suggest that combination therapy provides a novel therapeutic strategy for human osteosarcomas.
|
Report
(3 results)
Research Products
(16 results)